The GLP-1/GIP dual-receptor agonist tirzepatide led to at least 15% loss of total body fat in premenopausal, perimenopausal, and postmenopausal women, but postmenopausal women taking menopausal ...

Please provide your email address to receive an email when new articles are posted on . Most women with PCOS treated with tirzepatide experienced 5% or more, 10% or more and 15% or more weight loss.

Please provide your email address to receive an email when new articles are posted on . Use of hormonal birth control was linked with less weight loss after 12 months in a behavioral weight loss ...